Core Insights - Akoya Biosciences has launched a new assay aimed at enhancing antibody-drug conjugate (ADC) development for breast cancer, which will be showcased at the AACR 2025 Annual Meeting [1][2] - The new multiplex immunofluorescence (mIF) panel is designed to improve patient selection in breast cancer treatment, particularly with the rise of HER2- and TROP2-targeting ADCs [2][3] - The PhenoCode Discovery IO60 panel, which provides real-world data, demonstrates its effectiveness in immuno-oncology research, particularly in quantifying protein expression and analyzing biomarker efficacy [4][6] Company Developments - The ADC-focused panel includes key targets such as HER2, TROP2, Ki-67, and ER/PR, allowing for detailed analysis of ADC target expression and localization [3] - Akoya's Advanced Biopharma Services (ABS) offers comprehensive support for assay customization, imaging, and analysis, facilitating the transition from discovery to clinical application [3][4] - The company emphasizes the importance of spatial biology in translational research, aiming to provide tools that reflect the complexity of tumor microenvironments [3][6] Industry Impact - The introduction of the new ADC assay and the IO60 panel is expected to significantly influence therapeutic decision-making in breast cancer treatment [2][4] - The ability to identify specific patient cohorts, such as HER2-low and TROP2-high patients, is critical for enhancing the efficacy of ADC therapies [4] - Akoya's innovations are positioned to advance the field of spatial biology, providing researchers with the necessary tools to achieve patient-relevant outcomes [6][8]